Corvus Pharma

CORVUS PHARMACEUTICALS INC

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Pinterest,Mobile,App,On,The,Screen,Smartphone,Iphone,Closeup.,Pinterest

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

CETY

CRVS

FIGS

GDOT

GMED

IOVA

JBIO

NCNA

PINS

PROF

SHPH

TMDX

VEEE

WOLF

WORX

ZKIN

Pinterest sube un 12,7 % tras superar ingresos del primer trimestre y aumentar usuarios mensuales. Otras acciones también reaccionan.

Acciones de Pinterest (PINS) se disparan un 13%; Aquí están 20 acciones que se mueven en el premercado

Earnings

APDN

AUID

CERO

COMM

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharmaceuticals Inc

Health Care

Press Releases

General

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Management

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

ADC Therapeutics

Arcturus Therapeutics Holdings Inc. - Common Stock

Arcturus Therapeutics

Astria Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

CytomX Therapeutics

Emergent BioSolutions

enGene Holdings

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

I-MAB

Inhibrx Biosciences

KalVista Pharmaceuticals, Inc. - Common Stock

KalVista Pharmaceuticals

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

Neurogene

Ocugen

Organogenesis Holdings

Prothena Corporation plc - Ordinary Shares

Prothena Corp

RAPT Therapeutics

Rigel Pharmaceuticals, Inc. - Common Stock

Rigel Pharmaceuticals

Solid Biosciences

Savara

Verastem

XOMA Royalty

Mizuho

Oppenheimer

HC Wainwright & Co.

Ladenburg Thalmann

Comments

Corvus Pharma

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL